The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DNLI | +27.71% | -66.63% | -19.71% | -5% |
| S&P | +18.89% | +78.8% | +12.32% | +159% |
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Analysts maintained their buy ratings on the clinical-stage biotech company.
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$2,866.00K | -54.7% |
| Market Cap | $2.58B | -12.1% |
| Market Cap / Employee | $5.13M | 0.0% |
| Employees | 503 | 19.2% |
| Net Income | -$128,549.00K | -12.0% |
| EBITDA | -$134,499.00K | -5.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $205.33M | 17.4% |
| Accounts Receivable | $2.18M | 45.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $32.74M | -22.6% |
| Short Term Debt | $9.55M | -20.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -40.69% | -7.2% |
| Return On Invested Capital | -19.82% | 1.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$100,062.00K | -12.7% |
| Operating Free Cash Flow | -$98,538.00K | -17.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.58 | 1.81 | 2.06 | 2.61 | 17.56% |
| Price to Sales | 10.38 | 3094.13 | - | ||
| Price to Tangible Book Value | 1.58 | 1.81 | 2.06 | 2.61 | 17.56% |
| Enterprise Value to EBITDA | -10.88 | -11.72 | -12.64 | -15.40 | -26.68% |
| Return on Equity | -35.2% | -39.7% | -44.4% | -45.7% | 22.16% |
| Total Debt | $48.63M | $46.56M | $44.40M | $42.29M | -22.15% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
